Apricus Biosciences Announces National Phase Approval for Erectile Dysfunction Cream - Vitaros(R) in Germany

Apricus Biosciences Announces National Phase Approval for Erectile Dysfunction
Cream - Vitaros(R) in Germany

   First Topical, Fast-Acting, On-Demand Treatment for Erectile Dysfunction
                 Approved in One of Europe's Largest Markets

     Apricus Remains On-Track to Announce Additional Vitaros^® Partnering
                           Transactions in Q4 2013

SAN DIEGO, Oct. 7, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
("Apricus Bio" or the "Company") (Nasdaq:APRI) (www.apricusbio.com), today
announced that Germany's Federal Institute for Drugs and Medical Devices
(BfArM) has granted national phase approval to Vitaros^®, indicated for the
treatment of patients with erectile dysfunction ("ED"). The Company has now
received a total of five national phase approvals for Vitaros^®, including
Germany, Ireland, the Netherlands, Sweden and the United Kingdom ("UK").

"National phase approval of Vitaros^® in Germany, one of the largest ED
markets in Europe, is another important milestone for the Company," said
Richard Pascoe, Chief Executive Officer of Apricus Bio. "We look forward to
working with Sandoz, our commercialization partner in Germany, to move
Vitaros^® toward a successful launch in this key territory.Our regulatory
efforts, along with actions taken by our existing European partners,continue
to beon track to obtain the remaining five of ten European approvals from the
fourth quarter of 2013 through the first quarter of 2014."

In June 2013, Apricus Bio announced that its marketing application for
Vitaros^® was approved through the European Decentralized Procedure
("DCP").Under the DCP, Apricus Bio filed its application for marketing
approval designating Netherlands as the Reference Member State ("RMS") on
behalf of nine other European Concerned Member States ("CMS") participating in
the procedure.The Company continues to work independently, as well as with
its commercialization partners, to obtain country-by-country national phase
approvals in the remaining CMS territories including France, Italy, Spain,
Belgium and Luxembourg.Once the national phase approvals are secured on a
country-by-country basis, marketing of Vitaros^® can then be initiated in each
country by Apricus Bio's commercialization partners.

Once launched, Vitaros^® will become the first new and novel ED product in
nearly a decade, and with its unique product profile that addresses a large
number of patients who cannot or do not respond well to the existing
therapies, or who are intolerant to the systematic effects of PDE5 inhibitors,
it is well-positioned for commercial success.In Europe alone, the existing ED
products generated over $1 billion in sales in 2012.Apricus Bio believes that
a significant portion of the market remains untreated or under-treated, which
represents a substantial commercial opportunity for Vitaros^®.

Vitaros^® is currently partnered in key markets, including with Takeda in the
UK, Sandoz in Germany, Bracco in Italy and Abbott in Canada.Apricus Bio has
launched a comprehensive partnering process with the goal of licensing
Vitaros^® in the remaining un-partnered territories in Europe, Latin America
and North Africa. Apricus Bio has received and reviewed multiple bids for the
available territories and has narrowed the number of potential partners to a
select group with which it will negotiate terms. Moreover, the Company
remains on track to complete this process in the fourth quarter of this year.

About Vitaros^®

Vitaros^® has been approved for the treatment of Erectile Dysfunction ("ED")
by the European Health Authorities and by Health Canada. Vitaros^® is a
topically-applied cream formulation of alprostadil, a vasodilator, combined
with our proprietary permeation enhancer DDAIP.HCL, which directly increases
blood flow to the penis, causing an erection. Alprostadil is a widely accepted
alternative to the PDE-5 inhibitors for difficult to treat patients, and
Vitaros^®, which was determined to be safe and effective by the European
Health Authorities and previously by Health Canada, offers greater market
opportunity due to its patient-friendly form versus other alprostadil dosage
forms and also relative to oral ED products. With nearly 150 million men
worldwide who suffer from erectile dysfunction and an ED market size of
approximately $1 billion in revenue in Europe alone, Vitaros^® represents a
major market opportunity for Apricus Bio and its commercial partners given its
unique product profile and its potential to treat a large underserved
population.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops and
markets innovative treatments that help large patient populations across
numerous, large-market therapeutic classes including male and female sexual
health. The Company has one approved product, Vitaros^®, for the treatment of
erectile dysfunction, which is now approved in Europe and Canada and will be
commercialized by Apricus Bio's marketing partners, which include Abbott
Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG
(Sandoz), and Bracco SpA. Femprox^®, the Company's product candidate for the
treatment of female sexual arousal disorder, has successfully completed a
nearly 400-subject proof-of-concept study.

For further information on Apricus Bio, visit http://www.apricusbio.com.

Apricus Bio's Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended:
with the exception of the historical information contained in this release,
the matters described herein contain forward-looking statements that involve
risks and uncertainties that may individually or mutually impact the matters
herein described for a variety of reasons that are outside the control of the
Company, including, but not limited to, its ability to further develop its
product Vitaros^® for ED, and product candidate Femprox^® for Female Sexual
Interest and Arousal Disorder among others; to have its product and product
candidates receive additional patent protection and be approved by relevant
regulatory authorities in Europe, the United States, Canada and in other
countries, such as additional national phase approvals for Vitaros^® in the
remaining CMS territories; to successfully commercialize such product and
product candidates and other NexACT^® product candidates and drug delivery
technology; and to achieve its other development, commercialization and
financial goals. Readers are cautioned not to place undue reliance on these
forward-looking statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read the
risk factors set forth in the Company's most recent annual report on Form
10-K, subsequent quarterly reports filed on Form 10-Q and other filings made
with the SEC. Copies of these reports are available from the SEC's website or
without charge from the Company.

CONTACT: Apricus Bio Investor Relations:
        
         David Pitts or Lourdes Catala
         Argot Partners
         212-600-1902
         david@argotpartners.com
         lourdes@argotpartners.com

Apricus logo
 
Press spacebar to pause and continue. Press esc to stop.